![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | C07D 405/06 | |
C07D 319/16 | |||
A61K 31/4025 | |||
A61P 35/00 |
(11) | Patento numeris | 3599237 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 19182732.8 |
Europos patento paraiškos padavimo data | 2010-11-24 | |
(97) | Europos patento paraiškos paskelbimo data | 2020-01-29 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2021-03-24 |
(46) | Apibrėžties vertimo paskelbimo data |
(30) | Numeris | Data | Šalis |
26474809 P | 2009-11-27 | US |
(72) |
LIU, Hanlan, US
WILLIS, Chris, US
BHARDWAJ, Renu, US
COPELAND, Diane P., US
HARIANAWALA, Abizer, US
SKELL, Jeffrey, US
MARSHALL, John, US
KOCHLING, Jianmei, US
PALACE, Gerard, US
PETERSCHMITT, Judith, US
SIEGEL, Craig, US
CHENG, Seng, US
|
(73) |
Genzyme Corporation,
50 Binney Street, Cambridge, MA 02142,
US
|
(54) | PHARMACEUTICAL COMPOSITION OF THE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR ELIGLUSTAT FOR THE TREATMENT OF GAUCHER`S DISEASE COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P450 METABOLISM OF THE PATIENT |
PHARMACEUTICAL COMPOSITION OF THE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR ELIGLUSTAT FOR THE TREATMENT OF GAUCHER`S DISEASE COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P450 METABOLISM OF THE PATIENT |